Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that they will work together to develop clinical applications of ...

A Japanese health ministry panel has endorsed two products using iPS cells, paving the way for the world's first practical ...

The earliest they are likely to become available is around summer, after drug pricing has been finalized. These products will be covered by the public health insurance system. The out-of-pocket burden ...

Japan Approves Worlds First iPS Therapies for Parkinsons, Heart Failure Conditional approval granted for Sumitomo Pharmas ...

A Japanese health ministry expert panel is to discuss whether to endorse two products using iPS cells. The treatments are for heart disease and Parkinson's.

Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products prepared from iPS cell ...

TOKYO/OSAKA -- Japan on Thursday moved a step closer to approving the sale of two regenerative medicine products using ...

On February 19, an expert panel at the Ministry of Health, Labor and Welfare conditionally endorsed the manufacturing ...

Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson's disease Japan's health ministry panel on Thursday approved the ...

A recent study by a team led by Professor Shin Kaneko successfully induced regulatory T cell (Treg)-like cells from iPS cell-derived conventional helper T cells (Tconvs) and demonstrated their ability ...